Bio-Techne downgraded by Wells Fargo with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for TECH
Across the 26 sessions after earlier TECH headlines, the stock closed higher 14 times and lower 12 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TECH | SPY |
|---|---|---|---|
| Aug 13, 2026 | Bio-Techne Corrects Dividend Announcement | -0.1% | +0.7% |
| Aug 12, 2026 | Bio-Techne Releases Fourth Quarter Fiscal 2026 Resultsand 1 other headline that session | +0.1% | +0.3% |
| Jul 8, 2026 | Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio | +0.5% | -0.3% |
| Jun 25, 2026 | Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets | +20.1% | +0.1% |
| Jun 11, 2026 | Piper Sandler initiated coverage on Bio-Techne with a new price target | +2.9% | +1.7% |
| Jun 4, 2026 | Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization | +4.6% | +0.4% |
Quantisnow market dataNASDAQ
TECH
Bio-Techne Corp
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for TECH
Full TECH profile on Quantisnow Follow TECH and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time